BrainStorm Cell Therapeutics released new data on potential biomarkers from its Phase 2 trial investigating NurOwn, the company’s cell therapy for amyotrophic lateral sclerosis (ALS), at the International Symposium on ALS/MND meeting held in Boston last week. Both these findings and an ongoing Phase 3 trial, now recruiting patients in…
Pivotal Phase 3 clinical trial results presented at this year’s 28th International Symposium on ALS/MNDÂ reveal that Cytokinetics‘ investigational therapy tirasemtiv failed to provide a positive therapeutic impact on both muscle strength and slow vital capacity (SVC) in ALS patients. The results, which were presented by Jeremy Shefner, MD,…
The rate of ALS patients’ lung-function decline can predict their risk of breathing failure, their need for assisted ventilation, and their risk of death, according to Cytokinetics, a company that develops muscle-disease therapies. “These results suggest that respiratory function is an important prognostic indicator of clinical progression in people with…
Additional data on Radicava (edaravone) and the clinical trial that led to its approval to treat amyotrophic lateral sclerosis (ALS) will be presented in oral and poster presentations at the 28th International Symposium on ALS/MND that opens in Boston on Friday. Mitsubishi Tanabe Pharma America announced that its one oral…
An amyotrophic lateral sclerosis (ALS) diagnosis can be devastating for both the patient and their family. If a loved one has recently been diagnosed with ALS, they’ll need your support now more than ever. Remember to be understanding and patient. We’ve put together a list of things to consider if a someone close to you has…
In this TEDx Talks video, Steven Boeynaems explains that although we have known about amyotrophic lateral sclerosis (ALS) for 140 years, scientists still know very little about the condition that affects around 200,000 people worldwide. MORE: Seven interesting facts about ALS Boeynaems talks about the role of TDP-43 proteins and…
Using stem cell treatments to protect motor neurons is not enough to prevent the loss of nerve-muscle connections and disease progression in a mouse model of amyotrophic lateral sclerosis (ALS), researchers from Italy found. The study, published in the journal Stem Cell Research, had exposed mice to repeated brain…
Takeda Canada and the Montreal Neurological Institute (MNI) are teaming up to conduct joint research aimed at developing new therapies for amyotrophic lateral sclerosis (ALS). The collaborative effort includes developing and examining multiple cell assays from ALS patients over the next three years, from 2017 to 2020,…
https://vimeo.com/168979927 This short video from the ALS Association Texas Chapter shares the early symptoms of amyotrophic lateral sclerosis (ALS) using simple computer-generated animation. MORE: Discover seven facts about ALS you might find interesting ALS is difficult to diagnose in the early stages as the symptoms presented often mimic other diseases and conditions.
OK, so now I’m an official member of the ALS Boogie Board Club! No, it’s not a club for surfer-dudes with ALS. I’m using a Boogie Board Jot 8.5 eWriter, a unique gadget that replaces writing with pen and paper. I received it during my recent visit to the…
Get regular updates to your inbox.
